

Magle Group's CEO purchases shares from board member

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company's CEO Justin Pierace purchases 172,800 Magle Chemoswed shares from board member Malin Malmsjö.

The price per share is equal to 28 SEK per share which corresponds to the average closing price of the stock exchange during the ten preceding trading days. The transaction date is April 26, 2023.

Contacts

Megi Medzmariashvili, Legal Counsel, phone +46 (0)76 164 33 12, megi.medzmariashvili@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and <https://maglegroup.com/> and www.maglepharmaceut.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

[Magle Group's CEO purchases shares from board member](#)